24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
AHA News: Understanding the Basics of 'Herd Immunity'Multiple Measures of Social Distancing Required to Slow Coronavirus: StudyCough, Fever, Fatigue? Head to CDC's Online Coronavirus Symptom CheckerThree Countries Have Kept Coronavirus in Check; Here's How They Did ItTrial Finds Acupuncture May Help Prevent MigrainesSevere COVID-19 Might Injure the HeartWhy Are Teens, Millennials Ignoring Coronavirus Warnings?An Expert's Guide to Fact-Checking Coronavirus Info OnlineLivestock, Poultry Safe From Coronavirus: ExpertWuhan Study Shows How Social Distancing Is Saving LivesU.S. Hospital Beds Were Already Maxed Out Before Coronavirus PandemicFDA Warns of Defective EpiPen DangersPoll Finds High Anxiety in the Time of CoronavirusCould Robots Be Deployed to Front Line in Fighting COVID-19?COVID-19 May Force Some Cancer Patients to Delay TreatmentWhat People With Parkinson's Need to Know About COVID-19How to Weather Social Isolation During Coronavirus PandemicCOVID-19 Infection Likely Worse for Vapers, SmokersWhen Arteries Narrow, Chest Pain Can Come Earlier for Women Than MenLoss of Sense of Smell Could Be Early Sign of Coronavirus InfectionMany Drugs Already Approved by FDA May Have Promise Against COVID-19The Other Side of COVID-19: Milder Cases, Healthy RecoveryAs Coronavirus Myths Multiply, Experts Sort Fact From FictionA Third of Americans Ordered to Stay at Home; Summer Olympics Postponed for One YearWeight-Loss Surgery May Cut Risk of Heart Attack, StrokeFDA Warns Americans to Beware of Fake COVID-19 Test KitsTaking Steroids for Rheumatoid Arthritis, IBD? Your Odds for Hypertension May RiseWhat Does a Self-Quarantine Look Like?National Guard Activated in 3 States as U.S. Coronavirus Cases Top 34,000U.S. Coronavirus Cases Pass 26,000, With 1 in 4 Americans Under 'Shelter-in-Place' OrdersRaking Your Leaves to the Edge of Your Yard an Invitation to TicksNew Drug Helps Shrink Inoperable Tumors in KidsCoronavirus Crisis Should Put Elective Surgeries on Hold, Doctors' Group SaysAlmost Half of Coronavirus Patients Have Digestive SymptomsNearly 40% of Hospitalizations in U.S. COVID-19 Cases Involve Adults Under 55Healthy Living at Home to Ward Off CoronavirusWhat You Need to Know About Coronavirus If You Have AsthmaStudy Suggests COVID-19 Might Follow Seasonal PatternTrump Signs Massive Relief Package Into Law as U.S. Coronavirus Cases Reach 10,000AHA News: A Look at Allergies and Heart Health, With Tips to Endure Pollen Season Amid Coronavirus FearsNew Coronavirus Wasn't Made in a Lab, Genomic Study ShowsWho's Most at Risk From Coronavirus?The Most Effective Ways to Kill Coronavirus in Your HomeCoronavirus Cases Hit All 50 States, as U.S. Death Toll Tops 100AHA News: Working Out While Staying Safe During the Coronavirus OutbreakMedical Groups Say Heart Meds Don't Worsen COVID-19 SymptomsBelly Fat Can Lead to a Sudden Attack of Pancreatitis: StudyWith New Boost From Medicare, 'Telemedicine' Steps Up to Fight CoronavirusAnother Study Finds COVID-19 Typically Mild for KidsKeeping Coronavirus Anxiety at Bay
Questions and AnswersLinks
Related Topics

Diabetes

First Drug Approved for Treatment of Peanut Allergy in Children


HealthDay News
Updated: Feb 3rd 2020

new article illustration

MONDAY, Feb. 3, 2020 (HealthDay News) -- The U.S. Food and Drug Administration approved Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp) to alleviate allergic reactions to accidental peanut exposure, the agency announced late Friday.

Palforzia, a powder manufactured from peanuts, is indicated for initiation in individuals aged 4 to 17 years old with a confirmed peanut allergy. Treatment may be continued in individuals aged 4 years and older. "When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy," Peter Marks, M.D., Ph.D., director of the FDA Center for Biologics Evaluation and Research, said in an agency news release.

The FDA notes that Palforzia cannot be used for emergency treatment of allergic reactions. Treatment involves three phases, including initial dose escalation, given on a single day; up-dosing, which involves 11 increasing dose levels over several months; and maintenance. The initial dose escalation and the first dose of each up-dosing level are administered under the supervision of a health care professional. Once patients have completed all up-dosing levels, they can begin the maintenance phase. Palforzia is packaged in pull-apart color-coded capsules for the dose escalation and up-dosing levels and is packaged in a sachet for maintenance treatment. The powder from the capsules or sachet is to be mixed with a small amount of food such as applesauce, yogurt, or pudding for the patient to consume.

Approval was based on data from a randomized, double-blind, placebo-controlled study in about 500 peanut-allergic individuals. In an oral challenge after six months of maintenance treatment, 67.2 percent of individuals who received Palforzia tolerated a 600-mg dose of peanut protein with no more than mild allergic symptoms versus 4 percent of those who received placebo. In two double-blind, placebo-controlled studies of about 700 peanut-allergic individuals, the most commonly reported side effects with Palforzia included abdominal pain, vomiting, nausea, tingling in the mouth, itching in the mouth and ears, cough, runny nose, throat irritation and tightness, hives, wheezing, and shortness of breath and anaphylaxis.

Approval was granted to Aimmune Therapeutics.

More Information